Compared to recent studies from Europe, where the incidence of TSCI is between 15 and 30 per million population, the incidence of TSCI in Estonia is among the highest. The rates are significantly higher in men compared with women and especially among the youngest men. The leading cause of TSCI is falls. A significant proportion of injuries are related to alcohol consumption before trauma in Estonia.
Although the two cohorts had similar demographic, injury and clinical characteristics, the age profile of the victims was different. The incidence rate was 1.5 times higher and SMR was 2.7 times higher in Estonia. Probable explanations for the different outcomes of the two European countries are socioeconomic differences, lower physical activity level, lower life expectancy and insufficient injury prevention programmes in Estonia.
Our study shows that, when the cases that die at the scene of the accident are included, the incidence of TSCI in Estonia rises from 39.7 to 97.0 per million population.
Objective
To determine a predictive factor for the risk of conversion from ocular myasthenia gravis (
OMG
) to generalized
MG
(
GMG
) in a prospective study.
Methods
RNA
was isolated from serum samples and detection of micro
RNA
(mi
RNA
) expression analyzed with
qPCR
. In the discovery set, 179 human mi
RNA
s were assayed for profiling of five
OMG
patients and four age‐ and gender‐matched healthy controls. Based on the specific accumulation pattern of 19 mi
RNA
s from the discovery set, in addition to mi
RNA
s previously found elevated in generalized
MG
(
GMG
; miR‐150‐5p and miR‐30e‐5p), 21 mi
RNA
s were subsequently analyzed in a validation cohort of 83
OMG
patients (82 immunosuppression treatment naive; 49 male) within 3 months of diagnosis and at a follow‐up visit (median duration 28 months from first visit).
Results
Thirteen patients generalized 14.8 ± 12.0 months after the diagnosis and the majority (85%) belonged to the late onset
MG
group. Two mi
RNA
s were significantly higher in secondary
GMG
(
SGMG
) patients compared to
OMG
patients with late onset
MG
: miR‐30e‐5p (9.1 ± 0.5 vs. 6.3 ± 0.9;
P
< 0.0001) and miR‐150‐5p (7.4 ± 1.1 vs. 6.4 ± 1.1;
P
= 0.01). The sensitivity for miR‐30e‐5p in differentiating
OMG
and
SGMG
was 96% in all
OMG
patients and 100% in late onset
OMG
patients.
Interpretation
This is the first study to describe a potential predictive factor associated with the risk of generalization for patients with
OMG
. Raised levels (>8) of miR‐30e‐5p at initial presentation in patients with ocular
MG
symptoms, give a predictive cut‐off for subsequent generalization of 96–100%.
There are no biomarkers for late onset myasthenia gravis (LOMG; onset >50 years). We evaluated circulating microRNA in a discovery cohort of 4 LOMG patients and 4 healthy controls and in a prospective diagnostic validation cohort of 73 LOMG patients (48 male) with longitudinal follow-up samples. In immunosuppression naïve patients, levels of miRNAs miR-150-5p, miR-21-5p and miR-30e-5p decreased in parallel with clinical improvement after initiation of immunosuppression and their levels positively correlated with the clinical MG composite score. Levels of miR-150-5p and miR-21-5p were lower in patients with ocular compared to generalized LOMG. Circulating miR-150-5p, miR-21-5p and miR-30e-5p correlate with the clinical course in LOMG.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.